Promising Strategies for Overcoming BRAF Inhibitor Resistance Based on Known Resistance Mechanisms

Thompson, J.F.; Scolyer, R.A.; Kefford, R.F. Cutaneous melanoma. Lancet, 2005, 365(9460), 687-701.
[http://dx.doi.org/10.1016/S0140-6736(05)70937-5] [PMID: 15721476]

Martinelli, E.; Morgillo, F.; Troiani, T.; Ciardiello, F. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. Cancer Treat. Rev., 2017, 53, 61-69.
[http://dx.doi.org/10.1016/j.ctrv.2016.12.001] [PMID: 28073102]

Amaral, T.; Sinnberg, T.; Meier, F.; Krepler, C.; Levesque, M.; Niessner, H.; Garbe, C. The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition. Eur. J. Cancer, 2017, 73, 85-92.
[http://dx.doi.org/10.1016/j.ejca.2016.12.010] [PMID: 28169047]

Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M.J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B.A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G.J.; Bigner, D.D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J.W.; Leung, S.Y.; Yuen, S.T.; Weber, B.L.; Seigler, H.F.; Darrow, T.L.; Paterson, H.; Marais, R.; Marshall, C.J.; Wooster, R.; Stratton, M.R.; Futreal, P.A. Mutations of the BRAF gene in human cancer. Nature, 2002, 417(6892), 949-954.
[http://dx.doi.org/10.1038/nature00766] [PMID: 12068308]

Karoulia, Z.; Gavathiotis, E.; Poulikakos, P.I. New perspectives for targeting RAF kinase in human cancer. Nat. Rev. Cancer, 2017, 17(11), 676-691.
[http://dx.doi.org/10.1038/nrc.2017.79] [PMID: 28984291]

Liu, R.; Zhang, T.; Zhu, G.; Xing, M. Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer. Nat. Commun., 2018, 9(1), 579.
[http://dx.doi.org/10.1038/s41467-018-03033-1] [PMID: 29422527]

Hauschild, A.; Grob, J.J.; Demidov, L.V.; Jouary, T.; Gutzmer, R.; Millward, M.; Rutkowski, P.; Blank, C.U.; Miller, W.H.; Kaempgen, E.; Martin-Algarra, S.; Karaszewska, B.; Mauch, C.; Chiarion-Sileni, V.; Mirakhur, B.; Guckert, M.E.; Swann, R.S.; Haney, P.; Goodman, V.L.; Chapman, P.B. An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). J. Clin. Oncol., 2013, 31(15)
[http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9013]

Flaherty, K.T.; Robert, C.; Hersey, P.; Nathan, P.; Garbe, C.; Milhem, M.; Demidov, L.V.; Hassel, J.C.; Rutkowski, P.; Mohr, P.; Dummer, R.; Trefzer, U.; Larkin, J.M.; Utikal, J.; Dreno, B.; Nyakas, M.; Middleton, M.R.; Becker, J.C.; Casey, M.; Sherman, L.J.; Wu, F.S.; Ouellet, D.; Martin, A.M.; Patel, K.; Schadendorf, D.; Group, M.S. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med., 2012, 367(2), 107-114.
[http://dx.doi.org/10.1056/NEJMoa1203421] [PMID: 22663011]

Torres-Collado, A.X.; Knott, J.; Jazirehi, A.R. Reversal of resistance in targeted therapy of metastatic melanoma: Lessons learned from vemurafenib (BRAF(V600E)-Specific Inhibitor). Cancers (Basel), 2018, 10(6)
[http://dx.doi.org/10.3390/cancers10060157]

Flaherty, K.T.; Puzanov, I.; Kim, K.B.; Ribas, A.; McArthur, G.A.; Sosman, J.A.; O’Dwyer, P.J.; Lee, R.J.; Grippo, J.F.; Nolop, K.; Chapman, P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med., 2010, 363(9), 809-819.
[http://dx.doi.org/10.1056/NEJMoa1002011] [PMID: 20818844]

Falchook, G.S.; Long, G.V.; Kurzrock, R.; Kim, K.B.; Arkenau, T.H.; Brown, M.P.; Hamid, O.; Infante, J.R.; Millward, M.; Pavlick, A.C.; O’Day, S.J.; Blackman, S.C.; Curtis, C.M.; Lebowitz, P.; Ma, B.; Ouellet, D.; Kefford, R.F. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet, 2012, 379(9829), 1893-1901.
[http://dx.doi.org/10.1016/S0140-6736(12)60398-5] [PMID: 22608338]

Roskoski, R., Jr Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacol. Res., 2019, 144, 19-50.
[http://dx.doi.org/10.1016/j.phrs.2019.03.006] [PMID: 30877063]

Chapman, P.B.; Hauschild, A.; Robert, C.; Haanen, J.B.; Ascierto, P.; Larkin, J.; Dummer, R.; Garbe, C.; Testori, A.; Maio, M.; Hogg, D.; Lorigan, P.; Lebbe, C.; Jouary, T.; Schadendorf, D.; Ribas, A.; O’Day, S.J.; Sosman, J.A.; Kirkwood, J.M.; Eggermont, A.M.M.; Dreno, B.; Nolop, K.; Li, J.; Nelson, B.; Hou, J.; Lee, R.J.; Flaherty, K.T.; McArthur, G.A.; Grp, B-S. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med., 2011, 364(26), 2507-2516.
[http://dx.doi.org/10.1056/NEJMoa1103782] [PMID: 21639808]

Hauschild, A.; Grob, J.J.; Demidov, L.V.; Jouary, T.; Gutzmer, R.; Millward, M.; Rutkowski, P.; Blank, C.U.; Miller, W.H., Jr; Kaempgen, E.; Martín-Algarra, S.; Karaszewska, B.; Mauch, C.; Chiarion-Sileni, V.; Martin, A.M.; Swann, S.; Haney, P.; Mirakhur, B.; Guckert, M.E.; Goodman, V.; Chapman, P.B. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet, 2012, 380(9839), 358-365.
[http://dx.doi.org/10.1016/S0140-6736(12)60868-X]] [PMID: 22735384]

Menzies, A.M.; Long, G.V.; Murali, R. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des. Devel. Ther., 2012, 6, 391-405.
[PMID: 23251089]

Smith, M.P.; Wellbrock, C. Molecular pathways: Maintaining MAPK inhibitor sensitivity by targeting nonmutational tolerance. Clin. Cancer Res., 2016, 22(24), 5966-5970.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-0954] [PMID: 27797970]

Luke, J.J.; Flaherty, K.T.; Ribas, A.; Long, G.V. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat. Rev. Clin. Oncol., 2017, 14(8), 463-482.
[http://dx.doi.org/10.1038/nrclinonc.2017.43] [PMID: 28374786]

Dronca, R.S.; Allred, J.B.; Perez, D.G.; Nevala, W.K.; Lieser, E.A.; Thompson, M.; Maples, W.J.; Creagan, E.T.; Pockaj, B.A.; Kaur, J.S.; Moore, T.D.; Marchello, B.T.; Markovic, S.N. Phase II study of Temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: A North Central Cancer Treatment Group study, N0675. Am. J. Clin. Oncol., 2014, 37(4), 369-376.
[http://dx.doi.org/10.1097/COC.0b013e31827b45d4] [PMID: 23357973]

Tolcher, A.W.; Peng, W.; Calvo, E. Rational approaches for combination therapy strategies targeting the MAP kinase pathway in solid tumors. Mol. Cancer Ther., 2018, 17(1), 3-16.
[http://dx.doi.org/10.1158/1535-7163.MCT-17-0349] [PMID: 29295962]

Erdmann, S.; Seidel, D.; Jahnke, H.G.; Eichler, M.; Simon, J.C.; Robitzki, A.A. Induced cross-resistance of BRAF(V600E) melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment. Sci. Rep-Uk., 2019, 9, 11.

Ramos, P.; Bentires-Alj, M. Mechanism-based cancer therapy: Resistance to therapy, therapy for resistance. Oncogene, 2015, 34(28), 3617-3626.
[http://dx.doi.org/10.1038/onc.2014.314] [PMID: 25263438]

Arozarena, I.; Wellbrock, C. Overcoming resistance to BRAF inhibitors. Ann. Transl. Med., 2017, 5(19), 387.
[http://dx.doi.org/10.21037/atm.2017.06.09] [PMID: 29114545]

Lim, S.Y.; Menzies, A.M.; Rizos, H. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Cancer, 2017, 123(S11), 2118-2129.
[http://dx.doi.org/10.1002/cncr.30435] [PMID: 28543695]

Amaral, T.; Sinnberg, T.; Meier, F.; Krepler, C.; Levesque, M.; Niessner, H.; Garbe, C. MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition. Eur. J. Cancer, 2017, 73, 93-101.
[http://dx.doi.org/10.1016/j.ejca.2016.12.012] [PMID: 28162869]

Kozar, I.; Margue, C.; Rothengatter, S.; Haan, C.; Kreis, S. Many ways to resistance: How melanoma cells evade targeted therapies. Biochim. Biophys. Acta Rev. Cancer, 2019, 1871(2), 313-322.
[http://dx.doi.org/10.1016/j.bbcan.2019.02.002] [PMID: 30776401]

Shi, H.; Hugo, W.; Kong, X.; Hong, A.; Koya, R.C.; Moriceau, G.; Chodon, T.; Guo, R.; Johnson, D.B.; Dahlman, K.B.; Kelley, M.C.; Kefford, R.F.; Chmielowski, B.; Glaspy, J.A.; Sosman, J.A.; van Baren, N.; Long, G.V.; Ribas, A.; Lo, R.S. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov., 2014, 4(1), 80-93.
[http://dx.doi.org/10.1158/2159-8290.CD-13-0642] [PMID: 24265155]

Johnson, D.B.; Childress, M.A.; Chalmers, Z.R.; Frampton, G.M.; Ali, S.M.; Rubinstein, S.M.; Fabrizio, D.; Ross, J.S.; Balasubramanian, S.; Miller, V.A.; Stephens, P.J.; Sosman, J.A.; Lovly, C.M. BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy. Pigment Cell Melanoma Res., 2018, 31(3), 432-436.
[http://dx.doi.org/10.1111/pcmr.12674] [PMID: 29171936]

Rizos, H.; Menzies, A.M.; Pupo, G.M.; Carlino, M.S.; Fung, C.; Hyman, J.; Haydu, L.E.; Mijatov, B.; Becker, T.M.; Boyd, S.C.; Howle, J.; Saw, R.; Thompson, J.F.; Kefford, R.F.; Scolyer, R.A.; Long, G.V. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin. Cancer Res., 2014, 20(7), 1965-1977.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-3122] [PMID: 24463458]

Britten, C.D. PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemother. Pharmacol., 2013, 71(6), 1395-1409.
[http://dx.doi.org/10.1007/s00280-013-2121-1] [PMID: 23443307]

Shi, H.; Moriceau, G.; Kong, X.; Lee, M.K.; Lee, H.; Koya, R.C.; Ng, C.; Chodon, T.; Scolyer, R.A.; Dahlman, K.B.; Sosman, J.A.; Kefford, R.F.; Long, G.V.; Nelson, S.F.; Ribas, A.; Lo, R.S. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Commun., 2012, 3, 724.
[http://dx.doi.org/10.1038/ncomms1727] [PMID: 22395615]

Johnson, D.B.; Menzies, A.M.; Zimmer, L.; Eroglu, Z.; Ye, F.; Zhao, S.; Rizos, H.; Sucker, A.; Scolyer, R.A.; Gutzmer, R.; Gogas, H.; Kefford, R.F.; Thompson, J.F.; Becker, J.C.; Berking, C.; Egberts, F.; Loquai, C.; Goldinger, S.M.; Pupo, G.M.; Hugo, W.; Kong, X.; Garraway, L.A.; Sosman, J.A.; Ribas, A.; Lo, R.S.; Long, G.V.; Schadendorf, D. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur. J. Cancer, 2015, 51(18), 2792-2799.
[http://dx.doi.org/10.1016/j.ejca.2015.08.022] [PMID: 26608120]

Nazarian, R.; Shi, H.; Wang, Q.; Kong, X.; Koya, R.C.; Lee, H.; Chen, Z.; Lee, M.K.; Attar, N.; Sazegar, H.; Chodon, T.; Nelson, S.F.; McArthur, G.; Sosman, J.A.; Ribas, A.; Lo, R.S. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature, 2010, 468(7326), 973-977.
[http://dx.doi.org/10.1038/nature09626] [PMID: 21107323]

Poulikakos, P.I.; Rosen, N. Mutant BRAF melanomas--dependence and resistance. Cancer Cell, 2011, 19(1), 11-15.
[http://dx.doi.org/10.1016/j.ccr.2011.01.008] [PMID: 21251612]

Shi, H.; Kong, X.; Ribas, A.; Lo, R.S. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res., 2011, 71(15), 5067-5074.
[http://dx.doi.org/10.1158/0008-5472.CAN-11-0140] [PMID: 21803746]

Sun, C.; Wang, L.; Huang, S.; Heynen, G.J.; Prahallad, A.; Robert, C.; Haanen, J.; Blank, C.; Wesseling, J.; Willems, S.M.; Zecchin, D.; Hobor, S.; Bajpe, P.K.; Lieftink, C.; Mateus, C.; Vagner, S.; Grernrum, W.; Hofland, I.; Schlicker, A.; Wessels, L.F.; Beijersbergen, R.L.; Bardelli, A.; Di Nicolantonio, F.; Eggermont, A.M.; Bernards, R. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature, 2014, 508(7494), 118-122.
[http://dx.doi.org/10.1038/nature13121] [PMID: 24670642]

Girotti, M.R.; Pedersen, M.; Sanchez-Laorden, B.; Viros, A.; Turajlic, S.; Niculescu-Duvaz, D.; Zambon, A.; Sinclair, J.; Hayes, A.; Gore, M.; Lorigan, P.; Springer, C.; Larkin, J.; Jorgensen, C.; Marais, R. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov., 2013, 3(2), 158-167.
[http://dx.doi.org/10.1158/2159-8290.CD-12-0386] [PMID: 23242808]

Johannessen, C.M.; Boehm, J.S.; Kim, S.Y.; Thomas, S.R.; Wardwell, L.; Johnson, L.A.; Emery, C.M.; Stransky, N.; Cogdill, A.P.; Barretina, J.; Caponigro, G.; Hieronymus, H.; Murray, R.R.; Salehi-Ashtiani, K.; Hill, D.E.; Vidal, M.; Zhao, J.J.; Yang, X.; Alkan, O.; Kim, S.; Harris, J.L.; Wilson, C.J.; Myer, V.E.; Finan, P.M.; Root, D.E.; Roberts, T.M.; Golub, T.; Flaherty, K.T.; Dummer, R.; Weber, B.L.; Sellers, W.R.; Schlegel, R.; Wargo, J.A.; Hahn, W.C.; Garraway, L.A. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature, 2010, 468(7326), 968-972.
[http://dx.doi.org/10.1038/nature09627] [PMID: 21107320]

Mendoza, M.C.; Er, E.E.; Blenis, J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem. Sci., 2011, 36(6), 320-328.
[http://dx.doi.org/10.1016/j.tibs.2011.03.006] [PMID: 21531565]

Peng, S.B.; Henry, J.R.; Kaufman, M.D.; Lu, W.P.; Smith, B.D.; Vogeti, S.; Rutkoski, T.J.; Wise, S.; Chun, L.; Zhang, Y.; Van Horn, R.D.; Yin, T.; Zhang, X.; Yadav, V.; Chen, S.H.; Gong, X.; Ma, X.; Webster, Y.; Buchanan, S.; Mochalkin, I.; Huber, L.; Kays, L.; Donoho, G.P.; Walgren, J.; McCann, D.; Patel, P.; Conti, I.; Plowman, G.D.; Starling, J.J.; Flynn, D.L. Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers. Cancer Cell, 2015, 28(3), 384-398.
[http://dx.doi.org/10.1016/j.ccell.2015.08.002] [PMID: 26343583]

Whittaker, S.R.; Cowley, G.S.; Wagner, S.; Luo, F.; Root, D.E.; Garraway, L.A. Combined Pan-RAF and MEK inhibition overcomes multiple resistance mechanisms to selective RAF inhibitors. Mol. Cancer Ther., 2015, 14(12), 2700-2711.
[http://dx.doi.org/10.1158/1535-7163.MCT-15-0136-T] [PMID: 26351322]

Lu, H.; Liu, S.; Zhang, G.; Bin, W.; Zhu, Y.; Frederick, D.T.; Hu, Y.; Zhong, W.; Randell, S.; Sadek, N.; Zhang, W.; Chen, G.; Cheng, C.; Zeng, J.; Wu, L.W.; Zhang, J.; Liu, X.; Xu, W.; Krepler, C.; Sproesser, K.; Xiao, M.; Miao, B.; Liu, J.; Song, C.D.; Liu, J.Y.; Karakousis, G.C.; Schuchter, L.M.; Lu, Y.; Mills, G.; Cong, Y.; Chernoff, J.; Guo, J.; Boland, G.M.; Sullivan, R.J.; Wei, Z.; Field, J.; Amaravadi, R.K.; Flaherty, K.T.; Herlyn, M.; Xu, X.; Guo, W. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature, 2017, 550(7674), 133-136.
[http://dx.doi.org/10.1038/nature24040] [PMID: 28953887]

Flaherty, K.T.; Infante, J.R.; Daud, A.; Gonzalez, R.; Kefford, R.F.; Sosman, J.; Hamid, O.; Schuchter, L.; Cebon, J.; Ibrahim, N.; Kudchadkar, R.; Burris, H.A., III; Falchook, G.; Algazi, A.; Lewis, K.; Long, G.V.; Puzanov, I.; Lebowitz, P.; Singh, A.; Little, S.; Sun, P.; Allred, A.; Ouellet, D.; Kim, K.B.; Patel, K.; Weber, J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med., 2012, 367(18), 1694-1703.
[http://dx.doi.org/10.1056/NEJMoa1210093] [PMID: 23020132]

Van Allen, E.M.; Wagle, N.; Sucker, A.; Treacy, D.J.; Johannessen, C.M.; Goetz, E.M.; Place, C.S.; Taylor-Weiner, A.; Whittaker, S.; Kryukov, G.V.; Hodis, E.; Rosenberg, M.; McKenna, A.; Cibulskis, K.; Farlow, D.; Zimmer, L.; Hillen, U.; Gutzmer, R.; Goldinger, S.M.; Ugurel, S.; Gogas, H.J.; Egberts, F.; Berking, C.; Trefzer, U.; Loquai, C.; Weide, B.; Hassel, J.C.; Gabriel, S.B.; Carter, S.L.; Getz, G.; Garraway, L.A.; Schadendorf, D. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov., 2014, 4(1), 94-109.
[http://dx.doi.org/10.1158/2159-8290.CD-13-0617] [PMID: 24265153]

Trunzer, K.; Pavlick, A.C.; Schuchter, L.; Gonzalez, R.; McArthur, G.A.; Hutson, T.E.; Moschos, S.J.; Flaherty, K.T.; Kim, K.B.; Weber, J.S.; Hersey, P.; Long, G.V.; Lawrence, D.; Ott, P.A.; Amaravadi, R.K.; Lewis, K.D.; Puzanov, I.; Lo, R.S.; Koehler, A.; Kockx, M.; Spleiss, O.; Schell-Steven, A.; Gilbert, H.N.; Cockey, L.; Bollag, G.; Lee, R.J.; Joe, A.K.; Sosman, J.A.; Ribas, A. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J. Clin. Oncol., 2013, 31(14), 1767-1774.
[http://dx.doi.org/10.1200/JCO.2012.44.7888] [PMID: 23569304]

Wagle, N.; Emery, C.; Berger, M.F.; Davis, M.J.; Sawyer, A.; Pochanard, P.; Kehoe, S.M.; Johannessen, C.M.; Macconaill, L.E.; Hahn, W.C.; Meyerson, M.; Garraway, L.A. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol., 2011, 29(22), 3085-3096.
[http://dx.doi.org/10.1200/JCO.2010.33.2312] [PMID: 21383288]

Shi, H.; Moriceau, G.; Kong, X.; Koya, R.C.; Nazarian, R.; Pupo, G.M.; Bacchiocchi, A.; Dahlman, K.B.; Chmielowski, B.; Sosman, J.A.; Halaban, R.; Kefford, R.F.; Long, G.V.; Ribas, A.; Lo, R.S. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov., 2012, 2(5), 414-424.
[http://dx.doi.org/10.1158/2159-8290.CD-12-0022] [PMID: 22588879]

Emery, C.M.; Vijayendran, K.G.; Zipser, M.C.; Sawyer, A.M.; Niu, L.; Kim, J.J.; Hatton, C.; Chopra, R.; Oberholzer, P.A.; Karpova, M.B.; MacConaill, L.E.; Zhang, J.; Gray, N.S.; Sellers, W.R.; Dummer, R.; Garraway, L.A. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc. Natl. Acad. Sci. USA, 2009, 106(48), 20411-20416.
[http://dx.doi.org/10.1073/pnas.0905833106] [PMID: 19915144]

Shen, C.H.; Kim, S.H.; Trousil, S.; Frederick, D.T.; Piris, A.; Yuan, P.; Cai, L.; Gu, L.; Li, M.; Lee, J.H.; Mitra, D.; Fisher, D.E.; Sullivan, R.J.; Flaherty, K.T.; Zheng, B. Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. Nat. Med., 2016, 22(9), 1056-1061.
[http://dx.doi.org/10.1038/nm.4155] [PMID: 27500726]

Martz, C.A.; Ottina, K.A.; Singleton, K.R.; Jasper, J.S.; Wardell, S.E.; Peraza-Penton, A.; Anderson, G.R.; Winter, P.S.; Wang, T.; Alley, H.M.; Kwong, L.N.; Cooper, Z.A.; Tetzlaff, M.; Chen, P.L.; Rathmell, J.C.; Flaherty, K.T.; Wargo, J.A.; McDonnell, D.P.; Sabatini, D.M.; Wood, K.C. Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci. Signal., 2014, 7(357), ra121.
[http://dx.doi.org/10.1126/scisignal.aaa1877] [PMID: 25538079]

Zhu, G.; Yi, X.; Haferkamp, S.; Hesbacher, S.; Li, C.; Goebeler, M.; Gao, T.; Houben, R.; Schrama, D. Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells. Cancer Lett., 2016, 376(1), 43-52.
[http://dx.doi.org/10.1016/j.canlet.2016.03.028] [PMID: 27000992]

Zhang, K.; Wong, P.; Salvaggio, C.; Salhi, A.; Osman, I.; Bedogni, B. Synchronized targeting of Notch and ERBB signaling suppresses melanoma tumor growth through inhibition of Notch1 and ERBB3. J. Invest. Dermatol., 2016, 136(2), 464-472.
[http://dx.doi.org/10.1016/j.jid.2015.11.006] [PMID: 26967479]

Aguissa-Touré, A.H.; Li, G. Genetic alterations of PTEN in human melanoma. Cell. Mol. Life Sci., 2012, 69(9), 1475-1491.
[http://dx.doi.org/10.1007/s00018-011-0878-0] [PMID: 22076652]

Straussman, R.; Morikawa, T.; Shee, K.; Barzily-Rokni, M.; Qian, Z.R.; Du, J.; Davis, A.; Mongare, M.M.; Gould, J.; Frederick, D.T.; Cooper, Z.A.; Chapman, P.B.; Solit, D.B.; Ribas, A.; Lo, R.S.; Flaherty, K.T.; Ogino, S.; Wargo, J.A.; Golub, T.R. Tumour micro environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature, 2012, 487(7408), 500-504.
[http://dx.doi.org/10.1038/nature11183] [PMID: 22763439]

Wilson, T.R.; Fridlyand, J.; Yan, Y.; Penuel, E.; Burton, L.; Chan, E.; Peng, J.; Lin, E.; Wang, Y.; Sosman, J.; Ribas, A.; Li, J.; Moffat, J.; Sutherlin, D.P.; Koeppen, H.; Merchant, M.; Neve, R.; Settleman, J. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 2012, 487(7408), 505-509.
[http://dx.doi.org/10.1038/nature11249] [PMID: 22763448]

Villanueva, J.; Vultur, A.; Lee, J.T.; Somasundaram, R.; Fukunaga-Kalabis, M.; Cipolla, A.K.; Wubbenhorst, B.; Xu, X.; Gimotty, P.A.; Kee, D.; Santiago-Walker, A.E.; Letrero, R.; D’Andrea, K.; Pushparajan, A.; Hayden, J.E.; Brown, K.D.; Laquerre, S.; McArthur, G.A.; Sosman, J.A.; Nathanson, K.L.; Herlyn, M. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell, 2010, 18(6), 683-695.
[http://dx.doi.org/10.1016/j.ccr.2010.11.023] [PMID: 21156289]

Corcoran, R.B.; Ebi, H.; Turke, A.B.; Coffee, E.M.; Nishino, M.; Cogdill, A.P.; Brown, R.D.; Della Pelle, P.; Dias-Santagata, D.; Hung, K.E.; Flaherty, K.T.; Piris, A.; Wargo, J.A.; Settleman, J.; Mino-Kenudson, M.; Engelman, J.A. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov., 2012, 2(3), 227-235.
[http://dx.doi.org/10.1158/2159-8290.CD-11-0341] [PMID: 22448344]

Das Thakur, M.; Stuart, D.D. The evolution of melanoma resistance reveals therapeutic opportunities. Cancer Res., 2013, 73(20), 6106-6110.
[http://dx.doi.org/10.1158/0008-5472.CAN-13-1633] [PMID: 24097822]

Seghers, A.C.; Wilgenhof, S.; Lebbé, C.; Neyns, B. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Res., 2012, 22(6), 466-472.
[http://dx.doi.org/10.1097/CMR.0b013e3283541541] [PMID: 22584957]

Mateus, C.; Routier, E.; Roy, S.; Thomas, M.; Boussemart, L.; Glrault, I.; Chaput-Gras, N.; Vagner, S.; Cacenave, H.; Dalland, L.D.; Lau, M.R.; Bleam, M.R.; D’amelio, A.M.; Pfersch, S.; Caty, C.; Robert, C. Biomarker study evaluating the combination of dabrafenib (3) with trainetinib (T) versus the combination after 8 weeks of monotherapy with dabrafenib or trametinih in patients with metastatic and unresectable stage IIIC or IV melanoma: GSK study 116613. J. Clin. Oncol., 2014, 32(15)

Algazi, A.P.; Othus, M.; Daud, A.; Mehnert, J.M.; Lao, C.D.; Kudchadkar, R.R.; Grossmann, K.F.; Lo, R.; Moon, J.; Kirkwood, J.M.; Ribas, A. SWOG S1320: A randomized phase II trial of intermittent versus continuous dosing of dabrafenib and trametinib in BRAF(V600E/k) mutant melanoma. J. Clin. Oncol., 2015, 33(15)
[http://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps9093]

Block, K.I.; Gyllenhaal, C.; Lowe, L.; Amedei, A.; Amin, A.; Amin, A.; Aquilano, K.; Arbiser, J.; Arreola, A.; Arzumanyan, A.; Ashraf, S.S.; Azmi, A.S.; Benencia, F.; Bhakta, D.; Bilsland, A.; Bishayee, A.; Blain, S.W.; Block, P.B.; Boosani, C.S.; Carey, T.E.; Carnero, A.; Carotenuto, M.; Casey, S.C.; Chakrabarti, M.; Chaturvedi, R.; Chen, G.Z.; Chen, H.; Chen, S.; Chen, Y.C.; Choi, B.K.; Ciriolo, M.R.; Coley, H.M.; Collins, A.R.; Connell, M.; Crawford, S.; Curran, C.S.; Dabrosin, C.; Damia, G.; Dasgupta, S.; DeBerardinis, R.J.; Decker, W.K.; Dhawan, P.; Diehl, A.M.E.; Dong, J.T.; Dou, Q.P.; Drew, J.E.; Elkord, E.; El-Rayes, B.; Feitelson, M.A.; Felsher, D.W.; Ferguson, L.R.; Fimognari, C.; Firestone, G.L.; Frezza, C.; Fujii, H.; Fuster, M.M.; Generali, D.; Georgakilas, A.G.; Gieseler, F.; Gilbertson, M.; Green, M. Grue, B.; Guha, G.; Halicka, D.; Helferich, W.G.; Heneberg, P.; Hentosh, P.; Hirschey, M.D.; Hofseth, L.J.; Holcombe, R.F.; Honoki, K.; Hsu, H.Y.; Huang, G.S.; Jensen, L.D.; Jiang, W.G.; Jones, L.W.; Karpowicz, P.A.; Keith, W.N.; Kerkar, S.P.; Khan, G.N.; Khatami, M.; Ko, Y.H.; Kucuk, O.; Kulathinal, R.J.; Kumar, N.B.; Kwon, B.S.; Le, A.; Lea, M.A.; Lee, H.Y.; Lichtor, T.; Lin, L.T.; Locasale, J.W.; Lokeshwar, B.L.; Longo, V.D.; Lyssiotis, C.A.; MacKenzie, K.L.; Malhotra, M.; Marino, M.; Martinez-Chantar, M.L.; Matheu, A.; Maxwell, C.; McDonnell, E.; Meeker, A.K.; Mehrmohamadi, M.; Mehta, K.; Michelotti, G.A.; Mohammad, R.M.; Mohammed, S.I.; Morre, D.J.; Muralidhar, V.; Muqbil, I.; Murphy, M.P.; Nagaraju, G.P.; Nahta, R.; Niccolai, E.; Nowsheen, S.; Panis, C.; Pantano, F.; Parslow, V.R.; Pawelec, G.; Pedersen, P.L.; Poore, B.; Poudyal, D.; Prakash, S.; Prince, M.; Raffaghello, L.; Rathmell, J.C.; Rathmell, W.K.; Ray, S.K.; Reichrath, J.; Rezazadeh, S.; Ribatti, D.; Ricciardiello, L.; Robey, R.B.; Rodier, F.; Rupasinghe, H.P.V.; Russo, G.L.; Ryan, E.P.; Samadi, A.K.; Sanchez-Garcia, I.; Sanders, A.J.; Santini, D.; Sarkar, M.; Sasada, T.; Saxena, N.K.; Shackelford, R.E.; Shantha Kumara, H.M.C.; Sharma, D.; Shin, D.M.; Sidransky, D.; Siegelin, M.D.; Signori, E.; Singh, N.; Sivanand, S.; Sliva, D.; Smythe, C.; Spagnuolo, C.; Stafforini, D.M.; Stagg, J.; Subbarayan, P.R.; Sundin, T.; Talib, W.H.; Thompson, S.K.; Tran, P.T.; Ungefroren, H.; Vander Heiden, M.G.; Venkateswaran, V.; Vinay, D.S.; Vlachostergios, P.J.; Wang, Z.; Wellen, K.E.; Whelan, R.L.; Yang, E.S.; Yang, H.; Yang, X.; Yaswen, P.; Yedjou, C.; Yin, X.; Zhu, J.; Zollo, M. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin. Cancer Biol., 2015, 35(Suppl), S276-S304.

Kim, S.; Kim, H.T.; Suh, H.S. Combination therapy of BRAF inhibitors for advanced melanoma with BRAF V600 mutation: A systematic review and meta-analysis. J. Dermatolog. Treat., 2018, 29(3), 314-321.
[http://dx.doi.org/10.1080/09546634.2017.1330530] [PMID: 28504036]

Larkin, J.; Ascierto, P.A.; Dréno, B.; Atkinson, V.; Liszkay, G.; Maio, M.; Mandalà, M.; Demidov, L.; Stroyakovskiy, D.; Thomas, L.; de la Cruz-Merino, L.; Dutriaux, C.; Garbe, C.; Sovak, M.A.; Chang, I.; Choong, N.; Hack, S.P.; McArthur, G.A.; Ribas, A. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med., 2014, 371(20), 1867-1876.
[http://dx.doi.org/10.1056/NEJMoa1408868] [PMID: 25265494]

Menzies, A.M.; Ashworth, M.T.; Swann, S.; Kefford, R.F.; Flaherty, K.; Weber, J.; Infante, J.R.; Kim, K.B.; Gonzalez, R.; Hamid, O.; Schuchter, L.; Cebon, J.; Sosman, J.A.; Little, S.; Sun, P.; Aktan, G.; Ouellet, D.; Jin, F.; Long, G.V.; Daud, A. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. Ann. Oncol., 2015, 26(2), 415-421.
[http://dx.doi.org/10.1093/annonc/mdu529] [PMID: 25411413]

Long, G.V.; Trefzer, U.; Davies, M.A.; Kefford, R.F.; Ascierto, P.A.; Chapman, P.B.; Puzanov, I.; Hauschild, A.; Robert, C.; Algazi, A.; Mortier, L.; Tawbi, H.; Wilhelm, T.; Zimmer, L.; Switzky, J.; Swann, S.; Martin, A.M.; Guckert, M.; Goodman, V.; Streit, M.; Kirkwood, J.M.; Schadendorf, D. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol., 2012, 13(11), 1087-1095.
[http://dx.doi.org/10.1016/S1470-2045(12)70431-X] [PMID: 23051966]

Bollag, G.; Hirth, P.; Tsai, J.; Zhang, J.; Ibrahim, P.N.; Cho, H.; Spevak, W.; Zhang, C.; Zhang, Y.; Habets, G.; Burton, E.A.; Wong, B.; Tsang, G.; West, B.L.; Powell, B.; Shellooe, R.; Marimuthu, A.; Nguyen, H.; Zhang, K.Y.; Artis, D.R.; Schlessinger, J.; Su, F.; Higgins, B.; Iyer, R.; D’Andrea, K.; Koehler, A.; Stumm, M.; Lin, P.S.; Lee, R.J.; Grippo, J.; Puzanov, I.; Kim, K.B.; Ribas, A.; McArthur, G.A.; Sosman, J.A.; Chapman, P.B.; Flaherty, K.T.; Xu, X.; Nathanson, K.L.; Nolop, K. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 2010, 467(7315), 596-599.
[http://dx.doi.org/10.1038/nature09454] [PMID: 20823850]

Schreuer, M.; Jansen, Y.; Planken, S.; Chevolet, I.; Seremet, T.; Kruse, V.; Neyns, B. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual centre, phase 2 clinical trial. Lancet Oncol., 2017, 18(4), 464-472.
[http://dx.doi.org/10.1016/S1470-2045(17)30171-7] [PMID: 28268064]

Infante, J.R.; Falchook, G.S.; Lawrence, D.P.; Weber, J.S.; Kefford, R.F.; Bendell, J.C.; Kurzrock, R.; Shapiro, G.; Kudchadkar, R.R.; Long, G.V.; Burris, H.A.; Kim, K.B.; Clements, A.; Peng, S.; Yi, B.; Allred, A.J.; Ouellet, D.; Patel, K.; Lebowitz, P.F.; Flaherty, K.T. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). J. Clin. Oncol., 2011, 29(18)

Long, G.V.; Stroyakovsky, D.L.; Gogas, H.; Levchenko, E.; de Braud, F.; Larkin, J.M.G.; Garbe, C.; Jouary, T.; Hauschild, A.; Grob, J.J.; Chiarion-Sileni, V.; Lebbe, C.; Mandala, M.; Millward, M.; DeMarini, D.J.; Irani, J.G.; Le, N.; Casey, M.; Patel, K.; Flaherty, K. COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF(V600E/K) mutation-positive cutaneous melanoma. J. Clin. Oncol., 2014, 32(15)
[http://dx.doi.org/10.1200/jco.2014.32.15_suppl.9011]

Long, G.V.; Stroyakovskiy, D.; Gogas, H.; Levchenko, E.; de Braud, F.; Larkin, J.; Garbe, C.; Jouary, T.; Hauschild, A.; Grob, J.J.; Chiarion-Sileni, V.; Lebbe, C.; Mandalà, M.; Millward, M.; Arance, A.; Bondarenko, I.; Haanen, J.B.; Hansson, J.; Utikal, J.; Ferraresi, V.; Kovalenko, N.; Mohr, P.; Probachai, V.; Schadendorf, D.; Nathan, P.; Robert, C.; Ribas, A.; DeMarini, D.J.; Irani, J.G.; Swann, S.; Legos, J.J.; Jin, F.; Mookerjee, B.; Flaherty, K. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial. Lancet, 2015, 386(9992), 444-451.
[http://dx.doi.org/10.1016/S0140-6736(15)60898-4] [PMID: 26037941]

Flaherty, K.; Davies, M.A.; Grob, J.J.; Long, G.V.; Nathan, P.D.; Ribas, A.; Robert, C.; Schadendorf, D.; Frederick, D.T.; Hammond, M.R.; Jane-Valbuena, J.; Mu, X.J.; Squires, M.; Jaeger, S.A.; Lane, S.R.; Mookerjee, B.; Garraway, L.A. Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) plus trametinib (T) vs. D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. J. Clin. Oncol., 2016, 34(15)
[http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.9502]

Robert, C.; Karaszewska, B.; Schachter, J.; Rutkowski, P.; Mackiewicz, A.; Stroyakovskiy, D.; Dummer, R.; Grange, F.; Mortier, L.; Chiarion-Sileni, V.; Drucis, K.; Krajsová, I.; Hauschild, A.; Mookerjee, B.; Legos, J.J.; Zhang, Y.; Lane, S.; Schadendorf, D. Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma. Ann. Oncol., 2016, 27(suppl_6)

Robert, C.; Karaszewska, B.; Schachter, J.; Rutkowski, P.; Mackiewicz, A.; Stroiakovski, D.; Lichinitser, M.; Dummer, R.; Grange, F.; Mortier, L.; Chiarion-Sileni, V.; Drucis, K.; Krajsova, I.; Hauschild, A.; Lorigan, P.; Wolter, P.; Long, G.V.; Flaherty, K.; Nathan, P.; Ribas, A.; Martin, A.M.; Sun, P.; Crist, W.; Legos, J.; Rubin, S.D.; Little, S.M.; Schadendorf, D. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med., 2015, 372(1), 30-39.
[http://dx.doi.org/10.1056/NEJMoa1412690] [PMID: 25399551]

Su, F.; Viros, A.; Milagre, C.; Trunzer, K.; Bollag, G.; Spleiss, O.; Reis-Filho, J.S.; Kong, X.; Koya, R.C.; Flaherty, K.T.; Chapman, P.B.; Kim, M.J.; Hayward, R.; Martin, M.; Yang, H.; Wang, Q.; Hilton, H.; Hang, J.S.; Noe, J.; Lambros, M.; Geyer, F.; Dhomen, N.; Niculescu-Duvaz, I.; Zambon, A.; Niculescu-Duvaz, D.; Preece, N.; Robert, L.; Otte, N.J.; Mok, S.; Kee, D.; Ma, Y.; Zhang, C.; Habets, G.; Burton, E.A.; Wong, B.; Nguyen, H.; Kockx, M.; Andries, L.; Lestini, B.; Nolop, K.B.; Lee, R.J.; Joe, A.K.; Troy, J.L.; Gonzalez, R.; Hutson, T.E.; Puzanov, I.; Chmielowski, B.; Springer, C.J.; McArthur, G.A.; Sosman, J.A.; Lo, R.S.; Ribas, A.; Marais, R. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med., 2012, 366(3), 207-215.
[http://dx.doi.org/10.1056/NEJMoa1105358] [PMID: 22256804]

Ribas, A.; Gonzalez, R.; Pavlick, A.; Hamid, O.; Gajewski, T.F.; Daud, A.; Flaherty, L.; Logan, T.; Chmielowski, B.; Lewis, K.; Kee, D.; Boasberg, P.; Yin, M.; Chan, I.; Musib, L.; Choong, N.; Puzanov, I.; McArthur, G.A. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol., 2014, 15(9), 954-965.
[http://dx.doi.org/10.1016/S1470-2045(14)70301-8] [PMID: 25037139]

Puzanov, I. Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM). J. Transl. Med., 2015, 13(S1), 1-2.
[http://dx.doi.org/10.1186/1479-5876-13-S1-K8]

Larkin, J.M.G.; Yan, Y.B.; McArthur, G.A.; Ascierto, P.A.; Liszkay, G.; Maio, M.; Mandala, M.; Demidov, L.V.; Stroyakovskiy, D.; Thomas, L.; De La Cruz-Merino, L.; Atkinson, V.; Dutriaux, C.; Garbe, C.; Wongchenko, M.; Rooney, I.A.; Chang, I.S.; Hack, S.P.; Dreno, B.; Ribas, A. Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma. J. Clin. Oncol., 2015, 33(15)
[http://dx.doi.org/10.1200/jco.2015.33.15_suppl.9006]

Ascierto, P.A.; McArthur, G.A.; Dréno, B.; Atkinson, V.; Liszkay, G.; Di Giacomo, A.M.; Mandalà, M.; Demidov, L.; Stroyakovskiy, D.; Thomas, L.; de la Cruz-Merino, L.; Dutriaux, C.; Garbe, C.; Yan, Y.; Wongchenko, M.; Chang, I.; Hsu, J.J.; Koralek, D.O.; Rooney, I.; Ribas, A.; Larkin, J. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): Updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol., 2016, 17(9), 1248-1260.
[http://dx.doi.org/10.1016/S1470-2045(16)30122-X] [PMID: 27480103]

McArthur, G.A.; Larkin, J.M.G.; Ascierto, P.A.; Hsu, J.J.; Yan, Y.B.; Rooney, I.A.; Koralek, D.; Dreno, B.; Ribas, A. Efficacy of cobimetinib (C) and vemurafenib (V) in advanced BRAF-mutated melanoma patients (pts) with poor and favorable prognosis in the coBRIM phase III study. J. Clin. Oncol., 2016, 34(15)
[http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.9530]

Dossett, L.A.; Kudchadkar, R.R.; Zager, J.S. BRAF and MEK inhibition in melanoma. Expert Opin. Drug Saf., 2015, 14(4), 559-570.
[http://dx.doi.org/10.1517/14740338.2015.1011618] [PMID: 25648338]

Richman, J.; Martin-Liberal, J.; Diem, S.; Larkin, J. BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma. Expert Opin. Pharmacother., 2015, 16(9), 1285-1297.
[http://dx.doi.org/10.1517/14656566.2015.1044971] [PMID: 26001180]

Spagnolo, F.; Ghiorzo, P.; Orgiano, L.; Pastorino, L.; Picasso, V.; Tornari, E.; Ottaviano, V.; Queirolo, P. BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. OncoTargets Ther., 2015, 8, 157-168.
[http://dx.doi.org/10.2147/OTT.S39096] [PMID: 25653539]

Queirolo, P.; Picasso, V.; Spagnolo, F. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. Cancer Treat. Rev., 2015, 41(6), 519-526.
[http://dx.doi.org/10.1016/j.ctrv.2015.04.010] [PMID: 25944484]

Sweetlove, M.; Wrightson, E.; Kolekar, S.; Rewcastle, G.W.; Baguley, B.C.; Shepherd, P.R.; Jamieson, S.M. Inhibitors of pan-PI3K signaling synergize with BRAF or MEK inhibitors to prevent BRAF-mutant melanoma cell growth. Front. Oncol., 2015, 5, 135.
[http://dx.doi.org/10.3389/fonc.2015.00135] [PMID: 26137449]

Sánchez-Hernández, I.; Baquero, P.; Calleros, L.; Chiloeches, A. Dual inhibition of (V600E)BRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism. Cancer Lett., 2012, 314(2), 244-255.
[http://dx.doi.org/10.1016/j.canlet.2011.09.037] [PMID: 22056813]

Khalili, J.S.; Yu, X.; Wang, J.; Hayes, B.C.; Davies, M.A.; Lizee, G.; Esmaeli, B.; Woodman, S.E. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin. Cancer Res., 2012, 18(16), 4345-4355.
[http://dx.doi.org/10.1158/1078-0432.CCR-11-3227] [PMID: 22733540]

Poulikakos, P.I.; Persaud, Y.; Janakiraman, M.; Kong, X.; Ng, C.; Moriceau, G.; Shi, H.; Atefi, M.; Titz, B.; Gabay, M.T.; Salton, M.; Dahlman, K.B.; Tadi, M.; Wargo, J.A.; Flaherty, K.T.; Kelley, M.C.; Misteli, T.; Chapman, P.B.; Sosman, J.A.; Graeber, T.G.; Ribas, A.; Lo, R.S.; Rosen, N.; Solit, D.B. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature, 2011, 480(7377), 387-390.
[http://dx.doi.org/10.1038/nature10662] [PMID: 22113612]

Greger, J.G.; Eastman, S.D.; Zhang, V.; Bleam, M.R.; Hughes, A.M.; Smitheman, K.N.; Dickerson, S.H.; Laquerre, S.G.; Liu, L.; Gilmer, T.M. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol. Cancer Ther., 2012, 11(4), 909-920.
[http://dx.doi.org/10.1158/1535-7163.MCT-11-0989] [PMID: 22389471]

Villanueva, J.; Infante, J.R.; Krepler, C.; Reyes-Uribe, P.; Samanta, M.; Chen, H.Y.; Li, B.; Swoboda, R.K.; Wilson, M.; Vultur, A.; Fukunaba-Kalabis, M.; Wubbenhorst, B.; Chen, T.Y.; Liu, Q.; Sproesser, K.; DeMarini, D.J.; Gilmer, T.M.; Martin, A.M.; Marmorstein, R.; Schultz, D.C.; Speicher, D.W.; Karakousis, G.C.; Xu, W.; Amaravadi, R.K.; Xu, X.; Schuchter, L.M.; Herlyn, M.; Nathanson, K.L. Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep., 2013, 4(6), 1090-1099.
[http://dx.doi.org/10.1016/j.celrep.2013.08.023] [PMID: 24055054]

Tolcher, A.W.; Patnaik, A.; Papadopoulos, K.P.; Rasco, D.W.; Becerra, C.R.; Allred, A.J.; Orford, K.; Aktan, G.; Ferron-Brady, G.; Ibrahim, N.; Gauvin, J.; Motwani, M.; Cornfeld, M. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. Cancer Chemother. Pharmacol., 2015, 75(1), 183-189.
[http://dx.doi.org/10.1007/s00280-014-2615-5] [PMID: 25417902]

Hainsworth, J.D.; Infante, J.R.; Spigel, D.R.; Peyton, J.D.; Thompson, D.S.; Lane, C.M.; Clark, B.L.; Rubin, M.S.; Trent, D.F.; Burris, H.A., III Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: A phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer, 2010, 116(17), 4122-4129.
[http://dx.doi.org/10.1002/cncr.25320] [PMID: 20564157]

Morris, E.J.; Jha, S.; Restaino, C.R.; Dayananth, P.; Zhu, H.; Cooper, A.; Carr, D.; Deng, Y.; Jin, W.; Black, S.; Long, B.; Liu, J.; Dinunzio, E.; Windsor, W.; Zhang, R.; Zhao, S.; Angagaw, M.H.; Pinheiro, E.M.; Desai, J.; Xiao, L.; Shipps, G.; Hruza, A.; Wang, J.; Kelly, J.; Paliwal, S.; Gao, X.; Babu, B.S.; Zhu, L.; Daublain, P.; Zhang, L.; Lutterbach, B.A.; Pelletier, M.R.; Philippar, U.; Siliphaivanh, P.; Witter, D.; Kirschmeier, P.; Bishop, W.R.; Hicklin, D.; Gilliland, D.G.; Jayaraman, L.; Zawel, L.; Fawell, S.; Samatar, A.A. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov., 2013, 3(7), 742-750.
[http://dx.doi.org/10.1158/2159-8290.CD-13-0070] [PMID: 23614898]

Carlino, M.S.; Todd, J.R.; Gowrishankar, K.; Mijatov, B.; Pupo, G.M.; Fung, C.; Snoyman, S.; Hersey, P.; Long, G.V.; Kefford, R.F.; Rizos, H. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Mol. Oncol., 2014, 8(3), 544-554.
[http://dx.doi.org/10.1016/j.molonc.2014.01.003] [PMID: 24476679]

Liu, F.; Yang, X.; Geng, M.; Huang, M.; Targeting, E.R.K. Targeting ERK, an Achilles’ Heel of the MAPK pathway, in cancer therapy. Acta Pharm. Sin. B, 2018, 8(4), 552-562.
[http://dx.doi.org/10.1016/j.apsb.2018.01.008] [PMID: 30109180]

Moschos, S.J.; Sullivan, R.J.; Hwu, W.J.; Ramanathan, R.K.; Adjei, A.A.; Fong, P.C.; Shapira-Frommer, R.; Tawbi, H.A.; Rubino, J.; Rush, T.S., III; Zhang, D.; Miselis, N.R.; Samatar, A.A.; Chun, P.; Rubin, E.H.; Schiller, J.; Long, B.J.; Dayananth, P.; Carr, D.; Kirschmeier, P.; Bishop, W.R.; Deng, Y.; Cooper, A.; Shipps, G.W.; Moreno, B.H.; Robert, L.; Ribas, A.; Flaherty, K.T. Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight, 2018, 3(4), 18.
[http://dx.doi.org/10.1172/jci.insight.92352] [PMID: 29467321]

Germann, U.A.; Furey, B.F.; Markland, W.; Hoover, R.R.; Aronov, A.M.; Roix, J.J.; Hale, M.; Boucher, D.M.; Sorrell, D.A.; Martinez-Botella, G.; Fitzgibbon, M.; Shapiro, P.; Wick, M.J.; Samadani, R.; Meshaw, K.; Groover, A.; DeCrescenzo, G.; Namchuk, M.; Emery, C.M.; Saha, S.; Welsch, D.J. Targeting the MAPK signaling pathway in cancer: Promising preclinical activity with the novel selective ERK1/2 inhibitor BVD-523 (Ulixertinib). Mol. Cancer Ther., 2017, 16(11), 2351-2363.
[http://dx.doi.org/10.1158/1535-7163.MCT-17-0456] [PMID: 28939558]

Kidger, A.M.; Sipthorp, J.; Cook, S.J. ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway. Pharmacol. Ther., 2018, 187, 45-60.
[http://dx.doi.org/10.1016/j.pharmthera.2018.02.007] [PMID: 29454854]

Sullivan, R.J.; Infante, J.R.; Janku, F.; Wong, D.J.L.; Sosman, J.A.; Keedy, V.; Patel, M.R.; Shapiro, G.I.; Mier, J.W.; Tolcher, A.W.; Wang-Gillam, A.; Sznol, M.; Flaherty, K.; Buchbinder, E.; Carvajal, R.D.; Varghese, A.M.; Lacouture, M.E.; Ribas, A.; Patel, S.P.; DeCrescenzo, G.A.; Emery, C.M.; Groover, A.L.; Saha, S.; Varterasian, M.; Welsch, D.J.; Hyman, D.M.; Li, B.T. First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: Results of a Phase I dose-escalation and expansion study. Cancer Discov., 2018, 8(2), 184-195.
[http://dx.doi.org/10.1158/2159-8290.CD-17-1119] [PMID: 29247021]

Kalialis, L.V.; Drzewiecki, K.T.; Klyver, H. Spontaneous regression of metastases from melanoma: Review of the literature. Melanoma Res., 2009, 19(5), 275-282.
[http://dx.doi.org/10.1097/CMR.0b013e32832eabd5] [PMID: 19633580]

Maio, M. Melanoma as a model tumour for immuno-oncology. Ann. Oncol., 2012, 23(Suppl. 8), viii10-4.
[http://dx.doi.org/10.1093/annonc/mds257] [PMID: 22918922]

Melero, I.; Grimaldi, A.M.; Perez-Gracia, J.L.; Ascierto, P.A. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin. Cancer Res., 2013, 19(5), 997-1008.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-2214] [PMID: 23460531]

Sullivan, R.J.; Atkins, M.B. Cytokine therapy in melanoma. J. Cutan. Pathol., 2010, 37(Suppl. 1), 60-67.
[http://dx.doi.org/10.1111/j.1600-0560.2010.01507.x] [PMID: 20482677]

Atkins, M.B.; Lotze, M.T.; Dutcher, J.P.; Fisher, R.I.; Weiss, G.; Margolin, K.; Abrams, J.; Sznol, M.; Parkinson, D.; Hawkins, M.; Paradise, C.; Kunkel, L.; Rosenberg, S.A. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol., 1999, 17(7), 2105-2116.
[http://dx.doi.org/10.1200/JCO.1999.17.7.2105] [PMID: 10561265]

Joseph, R.W.; Sullivan, R.J.; Harrell, R.; Stemke-Hale, K.; Panka, D.; Manoukian, G.; Percy, A.; Bassett, R.L.; Ng, C.S.; Radvanyi, L.; Hwu, P.; Atkins, M.B.; Davies, M.A. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J. Immunother., 2012, 35(1), 66-72.
[http://dx.doi.org/10.1097/CJI.0b013e3182372636] [PMID: 22130161]

Eigentler, T.K.; Weide, B.; de Braud, F.; Spitaleri, G.; Romanini, A.; Pflugfelder, A.; González-Iglesias, R.; Tasciotti, A.; Giovannoni, L.; Schwager, K.; Lovato, V.; Kaspar, M.; Trachsel, E.; Menssen, H.D.; Neri, D.; Garbe, C. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin. Cancer Res., 2011, 17(24), 7732-7742.
[http://dx.doi.org/10.1158/1078-0432.CCR-11-1203] [PMID: 22028492]

Kirkwood, J.M.; Manola, J.; Ibrahim, J.; Sondak, V.; Ernstoff, M.S.; Rao, U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin. Cancer Res., 2004, 10(5), 1670-1677.
[http://dx.doi.org/10.1158/1078-0432.CCR-1103-3] [PMID: 15014018]

Eggermont, A.M.; Suciu, S.; Santinami, M.; Testori, A.; Kruit, W.H.; Marsden, J.; Punt, C.J.; Salès, F.; Gore, M.; Mackie, R.; Kusic, Z.; Dummer, R.; Hauschild, A.; Musat, E.; Spatz, A.; Keilholz, U.; Group, E.M. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet, 2008, 372(9633), 117-126.
[http://dx.doi.org/10.1016/S0140-6736(08)61033-8] [PMID: 18620949]

Hodi, F.S.; O’Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C.; Akerley, W.; van den Eertwegh, A.J.; Lutzky, J.; Lorigan, P.; Vaubel, J.M.; Linette, G.P.; Hogg, D.; Ottensmeier, C.H.; Lebbé, C.; Peschel, C.; Quirt, I.; Clark, J.I.; Wolchok, J.D.; Weber, J.S.; Tian, J.; Yellin, M.J.; Nichol, G.M.; Hoos, A.; Urba, W.J. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med., 2010, 363(8), 711-723.
[http://dx.doi.org/10.1056/NEJMoa1003466] [PMID: 20525992]

Brunet, J.F.; Denizot, F.; Luciani, M.F.; Roux-Dosseto, M.; Suzan, M.; Mattei, M.G.; Golstein, P. A new member of the immunoglobulin superfamily--CTLA-4. Nature, 1987, 328(6127), 267-270.
[http://dx.doi.org/10.1038/328267a0] [PMID: 3496540]

Schadendorf, D.; Hodi, F.S.; Robert, C.; Weber, J.S.; Margolin, K.; Hamid, O.; Chen, T.T.; Berman, D.M.; Wolchok, J.D. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. Eur. J. Cancer, 2013, 49, S11-S11.

Wolchok, J.D.; Weber, J.S.; Maio, M.; Neyns, B.; Harmankaya, K.; Chin, K.; Cykowski, L.; de Pril, V.; Humphrey, R.; Lebbé, C. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann. Oncol., 2013, 24(8), 2174-2180.
[http://dx.doi.org/10.1093/annonc/mdt161] [PMID: 23666915]

Weber, J.S.; Kähler, K.C.; Hauschild, A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol., 2012, 30(21), 2691-2697.
[http://dx.doi.org/10.1200/JCO.2012.41.6750] [PMID: 22614989]

Robert, C.; Thomas, L.; Bondarenko, I.; O’Day, S.; Weber, J.; Garbe, C.; Lebbe, C.; Baurain, J.F.; Testori, A.; Grob, J.J.; Davidson, N.; Richards, J.; Maio, M.; Hauschild, A.; Miller, W.H., Jr; Gascon, P.; Lotem, M.; Harmankaya, K.; Ibrahim, R.; Francis, S.; Chen, T.T.; Humphrey, R.; Hoos, A.; Wolchok, J.D. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med., 2011, 364(26), 2517-2526.
[http://dx.doi.org/10.1056/NEJMoa1104621] [PMID: 21639810]

Sherrill, B.; Wang, J.; Kotapati, S.; Chin, K. Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma. Br. J. Cancer, 2013, 109(1), 8-13.
[http://dx.doi.org/10.1038/bjc.2013.298] [PMID: 23787916]

Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B.; Leming, P.D.; Spigel, D.R.; Antonia, S.J.; Horn, L.; Drake, C.G.; Pardoll, D.M.; Chen, L.; Sharfman, W.H.; Anders, R.A.; Taube, J.M.; McMiller, T.L.; Xu, H.; Korman, A.J.; Jure-Kunkel, M.; Agrawal, S.; McDonald, D.; Kollia, G.D.; Gupta, A.; Wigginton, J.M.; Sznol, M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med., 2012, 366(26), 2443-2454.
[http://dx.doi.org/10.1056/NEJMoa1200690] [PMID: 22658127]

Freeman, G.J.; Long, A.J.; Iwai, Y.; Bourque, K.; Chernova, T.; Nishimura, H.; Fitz, L.J.; Malenkovich, N.; Okazaki, T.; Byrne, M.C.; Horton, H.F.; Fouser, L.; Carter, L.; Ling, V.; Bowman, M.R.; Carreno, B.M.; Collins, M.; Wood, C.R.; Honjo, T. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med., 2000, 192(7), 1027-1034.
[http://dx.doi.org/10.1084/jem.192.7.1027] [PMID: 11015443]

Topalian, S.L.; Drake, C.G.; Pardoll, D.M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol., 2012, 24(2), 207-212.
[http://dx.doi.org/10.1016/j.coi.2011.12.009] [PMID: 22236695]

Robert, C.; Ribas, A.; Wolchok, J.D.; Hodi, F.S.; Hamid, O.; Kefford, R.; Weber, J.S.; Joshua, A.M.; Hwu, W.J.; Gangadhar, T.C.; Patnaik, A.; Dronca, R.; Zarour, H.; Joseph, R.W.; Boasberg, P.; Chmielowski, B.; Mateus, C.; Postow, M.A.; Gergich, K.; Elassaiss-Schaap, J.; Li, X.N.; Iannone, R.; Ebbinghaus, S.W.; Kang, S.P.; Daud, A. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet, 2014, 384(9948), 1109-1117.
[http://dx.doi.org/10.1016/S0140-6736(14)60958-2] [PMID: 25034862]

Robert, C.; Schachter, J.; Long, G.V.; Arance, A.; Grob, J.J.; Mortier, L.; Daud, A.; Carlino, M.S.; McNeil, C.; Lotem, M.; Larkin, J.; Lorigan, P.; Neyns, B.; Blank, C.U.; Hamid, O.; Mateus, C.; Shapira-Frommer, R.; Kosh, M.; Zhou, H.; Ibrahim, N.; Ebbinghaus, S.; Ribas, A. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med., 2015, 372(26), 2521-2532.
[http://dx.doi.org/10.1056/NEJMoa1503093] [PMID: 25891173]

Iyer, P.C.; Dadu, R.; Gule-Monroe, M.; Busaidy, N.L.; Ferrarotto, R.; Habra, M.A.; Zafereo, M.; Williams, M.D.; Gunn, G.B.; Grosu, H.; Skinner, H.D.; Sturgis, E.M.; Gross, N.; Cabanillas, M.E. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J. Immunother. Cancer, 2018, 6(1), 68.
[http://dx.doi.org/10.1186/s40425-018-0378-y] [PMID: 29996921]

Ribas, A.; Robert, C.; Daud, A.; Hodi, F.S.; Wolchok, J.D.; Kefford, R.; Patnaik, A.; Hwu, W.J.; Weber, J.S.; Joshua, A.; Hersey, P.; Gangadhar, T.C.; Joseph, R.W.; Dronca, R.S.; Zarour, H.M.; Ebbinghaus, S.; Gergich, K.; Li, X.Y.; Kang, S.P.; Hamid, O. Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma. J. Clin. Oncol., 2013, 31(15)
[http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9009]

Wolchok, J.D.; Hoos, A.; O’Day, S.; Weber, J.S.; Hamid, O.; Lebbé, C.; Maio, M.; Binder, M.; Bohnsack, O.; Nichol, G.; Humphrey, R.; Hodi, F.S. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin. Cancer Res., 2009, 15(23), 7412-7420.
[http://dx.doi.org/10.1158/1078-0432.CCR-09-1624] [PMID: 19934295]

Hodi, F.S.; Kefford, R.; Hamid, O.; Daud, A.; Wolchok, J.D.; Hwu, W.J.; Gangadhar, T.C.; Patnaik, A.; Joshua, A.M.; Hersey, P. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with Melanoma (MEL). J. Clin. Oncol., 2014, 32(18_suppl), LBA9000.

Force, J.; Salama, A.K. First-line treatment of metastatic melanoma: role of nivolumab. ImmunoTargets Ther., 2017, 6, 1-10.
[http://dx.doi.org/10.2147/ITT.S110479] [PMID: 28243579]

Sosman, J.; Sznol, M.; McDermott, D.F.; Carvajal, R.; Lawrence, D.P.; Topalian, S.L.; Wigginton, J.M.; Kollia, G.; Gupta, A.; Hodi, F.S. Clinical activity and safety of anti-programmed death-1 (Pd-1) (Bms-936558/Mdx-1106/Ono-4538) in Patients (Pts) with Advanced Melanoma (Mel). Ann. Oncol., 2012, 23, 361-361.
[http://dx.doi.org/10.1093/annonc/mds404]

Weber, J.S.; Kudchadkar, R.R.; Gibney, G.T.; Yu, B.; Cheng, P.; Martinez, A.J.; Kroeger, J.; Gallenstein, D.; Richards, A.; Welsh, E.; Zhao, X.; Qu, X.; Chen, A. Updated survival, toxicity, and biomarkers of nivolumab with/without peptide vaccine in patients naive to, or progressed on, Ipilimumab (IPI). J. Clin. Oncol., 2014, 32(15_suppl), 3009-3009.

Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.; Hwu, W.J.; Topalian, S.L.; Hwu, P.; Drake, C.G.; Camacho, L.H.; Kauh, J.; Odunsi, K.; Pitot, H.C.; Hamid, O.; Bhatia, S.; Martins, R.; Eaton, K.; Chen, S.; Salay, T.M.; Alaparthy, S.; Grosso, J.F.; Korman, A.J.; Parker, S.M.; Agrawal, S.; Goldberg, S.M.; Pardoll, D.M.; Gupta, A.; Wigginton, J.M. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med., 2012, 366(26), 2455-2465.
[http://dx.doi.org/10.1056/NEJMoa1200694] [PMID: 22658128]

Hamid, O.; Robert, C.; Daud, A.; Hodi, F.S.; Hwu, W.J.; Kefford, R.; Wolchok, J.D.; Hersey, P.; Joseph, R.W.; Weber, J.S.; Dronca, R.; Gangadhar, T.C.; Patnaik, A.; Zarour, H.; Joshua, A.M.; Gergich, K.; Elassaiss-Schaap, J.; Algazi, A.; Mateus, C.; Boasberg, P.; Tumeh, P.C.; Chmielowski, B.; Ebbinghaus, S.W.; Li, X.N.; Kang, S.P.; Ribas, A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med., 2013, 369(2), 134-144.
[http://dx.doi.org/10.1056/NEJMoa1305133] [PMID: 23724846]

Hamid, O.; Sosman, J.A.; Lawrence, D.P.; Sullivan, R.J.; Ibrahim, N.; Kluger, H.M.; Boasberg, P.D.; Flaherty, K.; Hwu, P.; Ballinger, M.; Mokatrin, A.; Kowanetz, M.; Chen, D.S.; Hodi, F.S. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J. Clin. Oncol., 2013, 31(15)
[http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9010]

Ott, P.A.; Hodi, F.S.; Robert, C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin. Cancer Res., 2013, 19(19), 5300-5309.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-0143] [PMID: 24089443]

Lutzky, J.; Antonia, S.J.; Blake-Haskins, A.; Li, X.; Robbins, P.B.; Shaiabl, A.M.; Vasseill, J.; Ibrahim, R.A.; Khleif, S.; Segal, N.H. A phase 1 study of MEDI4736, an anti PD-L1 antibody, in patients with advanced solid tumors. J. Clin. Oncol., 2014, 32(15)
[http://dx.doi.org/10.1200/jco.2014.32.15_suppl.3001]

Segal, N.H.; Antonia, S.J.; Brahmer, J.R.; Maio, M.; Blake-Haskins, A.; Li, X.; Vasselli, J.; Ibrahim, R.A.; Lutzky, J.; Khieif, S. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. J. Clin. Oncol., 2014, 32(15)
[http://dx.doi.org/10.1200/jco.2014.32.15_suppl.3002]

Callahan, M.K.; Ott, P.A.; Odunsi, K.; Bertolini, S.V.; Pan, L.S.; Venhaus, R.R.; Karakunnel, J.J.; Hodi, F.S.; Wolchok, J.D. A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors. J. Clin. Oncol., 2014, 32(15)
[http://dx.doi.org/10.1200/jco.2014.32.15_suppl.tps3120]

Bellmunt, J.; Petrylak, D.P.; Powles, T.; Braiteh, F.; Vogelzang, N.; Cruz, C.; Burris, H.; Eder, J.P.; Fine, G.; Teng, M.S. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in Pts with metastatic Urothelial Bladder Cancer (UBC). Ann. Oncol., 2014, 25(suppl_4), iv280.

Heery, C.R.; Coyne, G.H.O.; Madan, R.A.; Schlom, J.; von Heydebreck, A.; Cuillerot, J.M.; Sabzevari, H.; Gulley, J.L. Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies. J. Clin. Oncol., 2014, 32(15)
[http://dx.doi.org/10.1200/jco.2014.32.15_suppl.3064]

Postow, M.A.; Chesney, J.; Pavlick, A.C.; Robert, C.; Grossmann, K.; McDermott, D.; Linette, G.P.; Meyer, N.; Giguere, J.K.; Agarwala, S.S.; Shaheen, M.; Ernstoff, M.S.; Minor, D.; Salama, A.K.; Taylor, M.; Ott, P.A.; Rollin, L.M.; Horak, C.; Gagnier, P.; Wolchok, J.D.; Hodi, F.S. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med., 2015, 372(21), 2006-2017.
[http://dx.doi.org/10.1056/NEJMoa1414428] [PMID: 25891304]

Wolchok, J.D.; Kluger, H.; Callahan, M.K.; Postow, M.A.; Rizvi, N.A.; Lesokhin, A.M.; Segal, N.H.; Ariyan, C.E.; Gordon, R.A.; Reed, K.; Burke, M.M.; Caldwell, A.; Kronenberg, S.A.; Agunwamba, B.U.; Zhang, X.; Lowy, I.; Inzunza, H.D.; Feely, W.; Horak, C.E.; Hong, Q.; Korman, A.J.; Wigginton, J.M.; Gupta, A.; Sznol, M. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med., 2013, 369(2), 122-133.
[http://dx.doi.org/10.1056/NEJMoa1302369] [PMID: 23724867]

Chapman, P.B.; D’Angelo, S.P.; Wolchok, J.D. Rapid eradication of a bulky melanoma mass with one dose of immunotherapy. N. Engl. J. Med., 2015, 372(21), 2073-2074.
[http://dx.doi.org/10.1056/NEJMc1501894] [PMID: 25891305]

Frederick, D.T.; Piris, A.; Cogdill, A.P.; Cooper, Z.A.; Lezcano, C.; Ferrone, C.R.; Mitra, D.; Boni, A.; Newton, L.P.; Liu, C.; Peng, W.; Sullivan, R.J.; Lawrence, D.P.; Hodi, F.S.; Overwijk, W.W.; Lizée, G.; Murphy, G.F.; Hwu, P.; Flaherty, K.T.; Fisher, D.E.; Wargo, J.A. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res., 2013, 19(5), 1225-1231.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-1630] [PMID: 23307859]

Wilmott, J.S.; Long, G.V.; Howle, J.R.; Haydu, L.E.; Sharma, R.N.; Thompson, J.F.; Kefford, R.F.; Hersey, P.; Scolyer, R.A. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res., 2012, 18(5), 1386-1394.
[http://dx.doi.org/10.1158/1078-0432.CCR-11-2479] [PMID: 22156613]

Ribas, A.; Hodi, F.S.; Callahan, M.; Konto, C.; Wolchok, J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med., 2013, 368(14), 1365-1366.
[http://dx.doi.org/10.1056/NEJMc1302338] [PMID: 23550685]

Sharma, P.; Hu-Lieskovan, S.; Wargo, J.A.; Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell, 2017, 168(4), 707-723.
[http://dx.doi.org/10.1016/j.cell.2017.01.017] [PMID: 28187290]

Boni, A.; Cogdill, A.P.; Dang, P.; Udayakumar, D.; Njauw, C.N.; Sloss, C.M.; Ferrone, C.R.; Flaherty, K.T.; Lawrence, D.P.; Fisher, D.E.; Tsao, H.; Wargo, J.A. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res., 2010, 70(13), 5213-5219.
[http://dx.doi.org/10.1158/0008-5472.CAN-10-0118] [PMID: 20551059]

Cooper, Z.A.; Juneja, V.R.; Sage, P.T.; Frederick, D.T.; Piris, A.; Mitra, D.; Lo, J.A.; Hodi, F.S.; Freeman, G.J.; Bosenberg, M.W.; McMahon, M.; Flaherty, K.T.; Fisher, D.E.; Sharpe, A.H.; Wargo, J.A. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol. Res., 2014, 2(7), 643-654.
[http://dx.doi.org/10.1158/2326-6066.CIR-13-0215] [PMID: 24903021]

Corcoran, R.B.; André, T.; Atreya, C.E.; Schellens, J.H.M.; Yoshino, T.; Bendell, J.C.; Hollebecque, A.; McRee, A.J.; Siena, S.; Middleton, G.; Muro, K.; Gordon, M.S.; Tabernero, J.; Yaeger, R.; O’Dwyer, P.J.; Humblet, Y.; De Vos, F.; Jung, A.S.; Brase, J.C.; Jaeger, S.; Bettinger, S.; Mookerjee, B.; Rangwala, F.; Van Cutsem, E. Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer. Cancer Discov., 2018, 8(4), 428-443.
[http://dx.doi.org/10.1158/2159-8290.CD-17-1226] [PMID: 29431699]

Prahallad, A.; Sun, C.; Huang, S.; Di Nicolantonio, F.; Salazar, R.; Zecchin, D.; Beijersbergen, R.L.; Bardelli, A.; Bernards, R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature, 2012, 483(7387), 100-103.
[http://dx.doi.org/10.1038/nature10868] [PMID: 22281684]

Al-Marrawi, M.Y.; Saroya, B.S.; Brennan, M.C.; Yang, Z.; Dykes, T.M.; El-Deiry, W.S. Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. Cancer Biol. Ther., 2013, 14(8), 703-710.
[http://dx.doi.org/10.4161/cbt.25191] [PMID: 23792568]

Cheng, H.; Chang, Y.; Zhang, L.; Luo, J.; Tu, Z.; Lu, X.; Zhang, Q.; Lu, J.; Ren, X.; Ding, K. Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib. J. Med. Chem., 2014, 57(6), 2692-2703.
[http://dx.doi.org/10.1021/jm500007h] [PMID: 24588073]

Awadallah, F.M.; Abou-Seri, S.M.; Abdulla, M.M.; Georgey, H.H. Design and synthesis of potent 1,2,4-trisubstituted imidazolinone derivatives with dual p38αMAPK and ERK1/2 inhibitory activity. Eur. J. Med. Chem., 2015, 94, 397-404.
[http://dx.doi.org/10.1016/j.ejmech.2015.03.008] [PMID: 25778995]